Skip to main content
SpringerLink
Log in

Fasting or Non-fasting Lipids for Atherosclerotic Cardiovascular Disease Risk Assessment and Treatment?

Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Dyslipidemia is a major modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD); however, lipid testing for risk assessment and treatment surveillance has been underutilized. Several factors likely account for this, including the common practice of measuring lipid levels in the fasting state, which often necessitates that patients return for an additional visit. In this review, we evaluate potential advantages and cautions associated with measuring lipids in the non-fasting state.

Recent Findings

There is similar performance with the use of either fasting or non-fasting total cholesterol and HDL cholesterol in ASCVD risk assessment. Observational studies demonstrate that in comparison to fasting levels, non-fasting triglycerides are approximately 20% higher on average, although the magnitude of difference is subject to substantial inter-patient variability. Higher triglycerides can lead to the under-estimation of low-density lipoprotein cholesterol (LDL-C) by approximately 10 mg/dL or more when calculated using the Friedewald equation. This is especially clinically relevant at low LDL-C levels, although a novel validated algorithm for LDL-C estimation largely overcomes this limitation.

Summary

Non-fasting lipid assessment is reasonable in many clinical circumstances given that ASCVD risk prediction is similar using fasting or non-fasting lipid values and because LDL-C can be accurately estimated using modern methods. Allowing the option for non-fasting lipid assessment can reduce a barrier to lipid testing and can facilitate a more convenient assessment of ASCVD risk with the ultimate potential effect of reducing the global burden of ASCVD. However, certain patients such as those with severe hypertriglyceridemias or high-risk patients being treated to low LDL-C levels may still need fasting lipid panels performed for precise diagnosis and to standardize therapeutic monitoring.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Driver SL, Martin SS, Gluckman TJ, Clary JM, Blumenthal RS, Stone NJ. Fasting or nonfasting lipid measurements: it depends on the question. J Am Coll Cardiol. 2016;67(10):1227–34. https://doi.org/10.1016/j.jacc.2015.12.047. Discusses the importance of placing the decision to fast or not fast in the clinical context.

    Article  CAS  PubMed  Google Scholar 

  2. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1–45. https://doi.org/10.1161/01.cir.0000437738.63853.7a.

    Article  PubMed  Google Scholar 

  3. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.

    CAS  PubMed  Google Scholar 

  4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–9.

  5. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–8. https://doi.org/10.1001/jama.285.13.1711.

    Article  CAS  PubMed  Google Scholar 

  6. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207. https://doi.org/10.1056/NEJMoa0807646.

    Article  CAS  PubMed  Google Scholar 

  7. National Cholesterol Education Program Expert Panel on Detection Evaluation Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.

    Google Scholar 

  8. Mansbach CM, Siddiqi SA. The biogenesis of chylomicrons. Annu Rev Physiol. 2010;72(1):315–33. https://doi.org/10.1146/annurev-physiol-021909-135801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sniderman A, Vu H, Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. Atherosclerosis. 1991;89(2–3):109–16. https://doi.org/10.1016/0021-9150(91)90050-D.

    Article  CAS  PubMed  Google Scholar 

  10. •• Sniderman A, Couture P, de Graaf J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol. 2010;6(6):335–46. https://doi.org/10.1038/nrendo.2010.50. Excellent review of how to diagnose genetic dyslipidemias.

    Article  CAS  PubMed  Google Scholar 

  11. Martin SS, Blaha MJ, Elshazly MB, Brinton EA, Toth PP, JW ME, et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol. 2013;62(8):732–9. https://doi.org/10.1016/j.jacc.2013.01.079.

    Article  CAS  PubMed  Google Scholar 

  12. Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem. 2002;48(2):236–54.

    CAS  PubMed  Google Scholar 

  13. Hps Timi Reveal Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13);1217–27. https://doi.org/10.1056/NEJMoa1706444.

  14. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22. https://doi.org/10.1056/NEJMoa1615664.

    Article  CAS  PubMed  Google Scholar 

  15. Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168(5):682–9. https://doi.org/10.1016/j.ahj.2014.07.028.

    Article  CAS  PubMed  Google Scholar 

  16. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, JC LR, Nestel PJ, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302–9. https://doi.org/10.1001/jama.2012.366.

    Article  CAS  PubMed  Google Scholar 

  17. Sondermeijer BM, Rana JS, Arsenault BJ, Shah PK, Kastelein JJ, Wareham NJ, et al. Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study. Eur J Clin Investig. 2013;43(10):1009–15. https://doi.org/10.1111/eci.12129.

    Article  CAS  Google Scholar 

  18. Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol. 2011;58(5):457–63. https://doi.org/10.1016/j.jacc.2011.05.009.

    Article  CAS  PubMed  Google Scholar 

  19. Sidhu D, Naugler C. Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med. 2012;172(22):1707–10. https://doi.org/10.1001/archinternmed.2012.3708.

    Article  CAS  PubMed  Google Scholar 

  20. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation. 2008;118(10):993–1001. https://doi.org/10.1161/CIRCULATIONAHA.108.777334.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Martin SS, Blaha MJ, Jones SR. Nonfasting lipids: there is the population and then there is the patient. JAMA Intern Med. 2013;173(10):935–6. https://doi.org/10.1001/jamainternmed.2013.383.

    Article  PubMed  Google Scholar 

  22. Cohn JS, JR MN, Schaefer EJ. Lipoprotein cholesterol concentrations in the plasma of human subjects as measured in the fed and fasted states. Clin Chem. 1988;34(12):2456–9.

    CAS  PubMed  Google Scholar 

  23. •• Sathiyakumar V, Park J, Golozar A, Lazo M, Quispe R, Guallar E et al. Fasting vs non-fasting and low-density lipoprotein-cholesterol accuracy. Circulation. 2017. Demonstrates the accuracy of a novel method to estimate LDL-C particularly in non-fasting samples and among patients with a LDL-C less than or equal to 70 mg/dL.

  24. Langsted A, Freiberg JJ, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Nordestgaard BG. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med. 2011;270(1):65–75. https://doi.org/10.1111/j.1365-2796.2010.02333.x.

    Article  CAS  PubMed  Google Scholar 

  25. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298(3):309–16. https://doi.org/10.1001/jama.298.3.309.

    Article  CAS  PubMed  Google Scholar 

  26. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008;300(18):2142–52. https://doi.org/10.1001/jama.2008.621.

    Article  CAS  PubMed  Google Scholar 

  27. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993–2000. https://doi.org/10.1001/jama.2009.1619.

    Article  Google Scholar 

  28. Doran B, Guo Y, Xu J, Weintraub H, Mora S, Maron DJ, et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation. 2014;130(7):546–53. https://doi.org/10.1161/CIRCULATIONAHA.114.010001.

    Article  CAS  PubMed  Google Scholar 

  29. Koopal C, Marais AD, Westerink J, Visseren FL. Autosomal dominant familial dysbetalipoproteinemia: a pathophysiological framework and practical approach to diagnosis and therapy. J Clin Lipidol. 2017;11(1):12–23 e1. https://doi.org/10.1016/j.jacl.2016.10.001.

    Article  PubMed  Google Scholar 

  30. Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132(22):2167–92. https://doi.org/10.1161/CIR.0000000000000297.

    Article  PubMed  Google Scholar 

  31. Cartier JL, Goldberg AC. Familial hypercholesterolemia: advances in recognition and therapy. Prog Cardiovasc Dis. 2016;59(2):125–34. https://doi.org/10.1016/j.pcad.2016.07.006.

    Article  PubMed  Google Scholar 

  32. Aldasouqi S, Sheikh A, Klosterman P, Kniestedt S, Schubert L, Danker R, et al. Hypoglycemia in patients with diabetes on antidiabetic medications who fast for laboratory tests. Diabetes Care. 2011;34(5):e52. https://doi.org/10.2337/dc10-2402.

    Article  PubMed  PubMed Central  Google Scholar 

  33. • Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37(25):1944–58. https://doi.org/10.1093/eurheartj/ehw152. Contends that non-fasting should be more routinely used in lipid assessment.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol. 2015;9(2):129–69. https://doi.org/10.1016/j.jacl.2015.02.003.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Blalock 524 A, Baltimore, MD, 21287, USA

    Faisal Rahman, Roger S. Blumenthal, Steven R. Jones, Seth S. Martin, Tyler J. Gluckman & Seamus P. Whelton

  2. Providence Heart and Vascular Institute, Portland, OR, USA

    Tyler J. Gluckman

Authors
  1. Faisal Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roger S. Blumenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven R. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seth S. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tyler J. Gluckman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Seamus P. Whelton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seamus P. Whelton.

Ethics declarations

Conflict of Interest

Faisal Rahman, Roger S. Blumenthal, Tyler J. Gluckman, and Seamus P. Whelton declare no conflict of interest. Steven R. Jones and Seth S. Martin are listed as co-inventors on a pending patent filed by Johns Hopkins University for novel LDL-C estimation. Seth S. Martin has served on scientific advisory boards for Quest Diagnostics, Sanofi-Regeneron, Amgen, and Akcea Therapeutics.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Coronary Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rahman, F., Blumenthal, R.S., Jones, S.R. et al. Fasting or Non-fasting Lipids for Atherosclerotic Cardiovascular Disease Risk Assessment and Treatment?. Curr Atheroscler Rep 20, 14 (2018). https://doi.org/10.1007/s11883-018-0713-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-018-0713-2

Keywords

search

Navigation